Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,668 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Completed Phase 3 Interventional Results available

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

NCT04385368
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab + SoC chemotherapy, Placebo + SoC chemotherapy
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Santa Rosa, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 20, 2026, 3:06 PM EDT
Recruiting Phase 3 Interventional

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

NCT07226232
View directory record Official record
Conditions
Major Depression
Interventions
Psilocybin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Not applicable Interventional Results available

Presumptively Initiating Vaccines and Optimizing Talk With Motivational Interviewing (PIVOT With MI)

NCT03885232
View directory record Official record
Conditions
Preventive Health Services (PREV HEALTH SERV)
Interventions
Experimental: PIVOT with MI, Active Comparator: Control
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Day to 18 Months
Enrollment
17,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Not applicable Interventional

Mental Practice in Chronic, Stroke Induced Hemiparesis

NCT01651533
View directory record Official record
Conditions
Hemiparesis
Interventions
Mental Practice Group, Active Control Group
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 20, 2026, 3:06 PM EDT
Not yet recruiting Not applicable Interventional

Study of Shunt Flow Under Different Valve Settings Using a Wireless Sensor

NCT07679035
View directory record Official record
Conditions
Hydrocephalus
Interventions
Rhaeos Shunt Monitoring System (RSMS), ShuntCheck III
Device
Lead sponsor
Rhaeos, Inc.
Industry
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

NCT00766363
View directory record Official record
Conditions
Alzheimer's Disease, Central Nervous System Diseases
Interventions
EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

NCT01409915
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Sagramostim, Saline -- placebo comparator
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 20, 2026, 3:06 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

NCT06843317
View directory record Official record
Conditions
RSV Infection
Interventions
Candidate vaccine, SCB-1019T, AREXVY, placebo
Biological · Other
Lead sponsor
Clover Biopharmaceuticals USA, LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

NCT01147666
View directory record Official record
Conditions
End Stage Renal Disease, Anemia
Interventions
Roxadustat, Epoetin Alfa, Placebo
Drug · Other
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 20, 2026, 3:06 PM EDT
Recruiting Phase 1 Interventional

Impact of Daily Oral Cannabis Doses in Patients With Cancer

NCT06601218
View directory record Official record
Conditions
Cancer, Cancers, Pain
Interventions
Oral cannabis low THC, Placebo Comparator, Oral cannabis high THC, Oral cannabis THC/CBD
Drug
Lead sponsor
Shanna Babalonis, PhD
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients

NCT02260791
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
FKB327, Humira®
Drug
Lead sponsor
Fujifilm Kyowa Kirin Biologics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Peoria, Arizona • Palm Desert, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of a DeskCycle to Reduce Sedentary Behavior During the Workday

NCT05412797
View directory record Official record
Conditions
Chronic Disease, Reduction, Weight
Interventions
Cycling/Using a DeskCycle, Regular activities
Behavioral
Lead sponsor
Kent State University
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kent, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

NCT02867735
View directory record Official record
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
Interventions
LKA651, Sham Comparator
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Pasadena, California • Fort Myers, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2022 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

NCT00510484
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Pancrelipase Delayed Release, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile Attention Retraining in Overweight Female Adolescents

NCT02977403
View directory record Official record
Conditions
Obesity, Overweight, Binge Eating, Healthy Volunteers
Interventions
Attention Bias Retraining, Sham Comparator: AB Control
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 21 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated

NCT05045183
View directory record Official record
Conditions
Wound Healing
Interventions
SoC Adhesive Bandage, Antibiotic Ointment, Antiseptic Wash, Hydrocolloid Pad
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 20, 2026, 3:06 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use

NCT00535769
View directory record Official record
Conditions
Skin Cancer
Interventions
Electronic + no text message, Electronic monitor + text messages
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Not applicable Interventional

Fluoroscopy Guided Femoral Arterial Access

NCT00222430
View directory record Official record
Conditions
Vascular Access
Interventions
Fluoroscopy, Active Comparator
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 1 Interventional

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

NCT01290965
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Placebo, SCY-635
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

NCT01694186
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI insert, Sham injection
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Not applicable Interventional

Study to Identify if OVR Health's VR-Kit is Safe to Use and Helps to Improve Focus, Attention and Reduce Worry & Rumination.

NCT05291429
View directory record Official record
Conditions
Anxiety, Depression, Anxiety
Interventions
OVR Health's VR experience
Device
Lead sponsor
Oxford VR
Industry
Eligibility
18 Years to 79 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 20, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

NCT01515657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 20, 2026, 3:06 PM EDT